Lilly's (LLY) CYRAMZA Phase 3 RELAY Trial Met Primary Endpoint, Significantly Improving PSFl in First-Line Treatment of Patients with Metastatic EGFR-Mutated NSCLC

March 12, 2019 6:46 AM
Eli Lilly and Company (NYSE: LLY) today announced that its Phase 3 RELAY study of CYRAMZA® (ramucirumab) met its primary ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Hot FDA News Management Comments

Next Articles